Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type1 Diabetes Mellitus
Conditions
Type1 Diabetes Mellitus
Trial Timeline
Feb 17, 2017 → May 3, 2017
NCT ID
NCT02910518About Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin
Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin is a phase 1 stage product being developed by Sanofi for Type1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT02910518. Target conditions include Type1 Diabetes Mellitus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02910518 | Phase 1 | Completed |
Competing Products
11 competing products in Type1 Diabetes Mellitus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose | Precigen | Phase 1/2 | 36 |
| Insulin Lispro | Eli Lilly | Phase 1 | 33 |
| LY900014 + Insulin Lispro | Eli Lilly | Phase 2 | 52 |
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Dapagliflozin + Placebo Oral Tablet | AstraZeneca | Phase 1 | 33 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 51 |
| Aspart | Novo Nordisk | Approved | 84 |
| Insulin glargine new formulation HOE901 | Sanofi | Phase 1 | 32 |
| verapamil 120mg tablet + placebo | Dexcom | Phase 3 | 74 |
| UP421 | Sana Biotechnology | Phase 1 | 28 |
| XeriSol glucagon | Xeris Pharmaceuticals | Phase 1 | 28 |